iCAD
Healthcare Software · New Hampshire, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
98 Spit Brook Rd Ste 100, Nashua, New Ha...Phone Number
(603) 882-5200Website
www.icadmed.comRevenue
$19.6 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
2
3
2
2
About iCAD
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer cant hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCADs industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation.Explore more
iCAD Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iCAD your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if iCAD has recently received funding, and reach out quickly before it becomes old news!
Click to see if iCAD had a recent Job posting/layoffs
Check out if iCAD is spiking on competitors!
Product Launch: Get notified when iCAD launches new products
Earning: See what the market has to say on iCAD recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once iCAD has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at iCAD
iCAD, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to iCAD
Compare insights from companies similar to iCAD, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
iCAD is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
iCAD is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about iCAD.
iCAD financials insights
Gather financial insights about iCAD, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Share Placement
$15M
2019
Stock Offering
$10.3M
2020
Stock Offering
$12.5M
iCAD Tech Stack
A closer look at the technologies used by iCAD
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Training, Sales, Search, Medical Research, Clinical Operations, Field Marketing, Healthcare Operations, Healthcare Technology, Operations, Radiology
Award
Award, Finance, Healthcare Technology
Person-Based
Person-Based
Person-Based
iCAD News & Media
RadNet finalizes $103M acquisition of breast AI vendor iCAD amid legal opposition
ICAD shareholders filed suit against the transaction last month in New York, claiming financial estimates used in the deal are misleading.RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD
LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in AI-powered breast health solutions. The integration of iCAD's complementary commercial, technology, and regulatory capabilities into DeepHealth advances DeepHealth’s mission to addresiCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.
NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have each recommended that stockholders vote “FOR” the previously announced acquisition of the Company by RadNet, Inc. (“RadNet”) at the Company’s upcoming Special Meeting ofICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the
Read more news
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iCAD
Sign Up For FreeTo access detailed company insights
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer cant hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCADs industry-leading ProFound Breast Health Suite provide... Read More
